A team of researchers from the University of Tennessee Graduate School of Medicine has spent more than two decades investigating systemic amyloidosis, a rare and often fatal disorder with few treatments. Their work played an integral role in moving discoveries out of the lab and into clinical trials, helping launch a biopharmaceutical company focused on (read more)
Multi Campus Office
UTRF Licensee Attralus Secures $25M in Investment
Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on (read more)
UTRF’s Commercialization Analyst Program Goes Virtual, Offers Unique Commercialization Insight
For the past nine years, the University of Tennessee Research Foundation’s internship program has offered valuable career experience to UT law students, graduate students, and post-doctoral researchers interested in the commercialization process of innovations from the University of Tennessee. This year, the program has gone virtual due to the COVID-19 pandemic. Interns in UTRF’s Commercialization (read more)